CaroGen
Hamden
About CaroGen
CaroGen Corporation is an emerging biopharmaceutical company with an entirely new platform technology developed by Professor John Rose at Yale University School of Medicine. We are dedicated to creating recombinant and replication proficient-virus like vesicle (VLV)-based vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $11.3M
- Funding stage: Seed
- Last round: Grant (Dec 2023)
- Website: carogencorp.com
- Phone: 203-230-8596
Industries & Categories
Biopharma, Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/carogen-21106 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.